EUVIMEDEUVIMED entdecken
Crossref

Epitope-Based Multimeric Subunit Vaccine (ATOMSSUISpenta) Confers Broad Protection Against Streptococcus suis Infection

Sun-Young Kim iD, Fengjia Chen, Woo-Sik Kim, Hyun Jung Ji, Min-Kyu Kim iD, Hae Ran Park, Charles Euloge Lamien, Viskam Wijewardana, Kyung-Hyo Kim iD, Ki Bum Ahn iD, Ho Seong Seo iD

The Journal of Infectious Diseases · 15.05.2026 · 233 (5) · 899-911

DOI: 10.1093/infdis/jiag131 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 04.03.2026. Verfasst von Sun-Young Kim und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cyclotron Applied Research Section, Korea Atomic Energy Research Institute, Jeongeup, Republic of Korea. Hauptthemen laut MEDLINE: Streptococcus suis, Streptococcal Infections, Streptococcal Vaccines, Epitopes, B-Lymphocyte. Die Arbeit nennt 46 Literaturangaben. Gefördert von: Korea Atomic Energy Research Institute, Ministry of Science and ICT, Ministry of Food and Drug Safety.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Streptococcus suis (S. suis) is a zoonotic pathogen causing economic losses in the swine industry and severe human infections. High serotype variability and genomic diversity of S. suis hinder cross-protective vaccine development. Although advances in in silico prediction-driven antigen discovery have accelerated protein vaccine development, discrepancies between predicted immunogenicity and experimentally verified protection in animal models emphasize the need to integrate computational design with empirical validation.

Methods

Using an in silico design strategy, predicted T- and B-cell epitope-rich domains from S. suis antigens (HP0197, Fnbp, Sao, ScpB, and SLY) were assembled into a multimeric vaccine, ATOMSSUISpenta, optimized for predicted immunogenicity, solubility, and allergenicity. Vaccine efficacy was evaluated in mice through antibody profiling, cellular immunity analysis, and assessment of cross-serotype immunity.

Results

ATOMSSUISpenta elicited strong humoral responses against all component antigens. The vaccine also induced Th1- and Th17-type cellular responses, critical for opsonic and mucosal defense against S. suis. In addition, ATOMSSUISpenta conferred significant protection in a S. suis serotype 2 infection and induced opsonic antibodies against serotypes 4 and 9.

Conclusions

These findings highlight ATOMSSUISpenta as a subunit vaccine strategy with potential for broader protection and demonstrate the effectiveness of epitope-based multimeric design against antigenically diverse Gram-positive pathogens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Streptococcus suisStreptococcal InfectionsStreptococcal VaccinesEpitopes, B-LymphocyteEpitopes, T-LymphocyteSwine DiseasesAnimalsVaccines, SubunitMiceAntibodies, BacterialProtein Subunit VaccinesAntigens, BacterialFemaleSwineImmunity, CellularCross Protection

Stichwörter der Autor:innen

Streptococcus suiscross-serotype immunityepitope-based designimmunogenicityprotein subunit vaccine

Substanzen

Streptococcal VaccinesVaccines, SubunitEpitopes, B-LymphocyteAntibodies, BacterialProtein Subunit VaccinesEpitopes, T-LymphocyteAntigens, Bacterial

Autor:innen und Institutionen

  • Cyclotron Applied Research Section, Korea Atomic Energy Research Institute, Jeongeup, Republic of Korea.
  • School of Biological Sciences, Seoul National University, Seoul, Republic of Korea.
  • Functional Biomaterial Research Center, Korea Research Institute of Bioscience and Biotechnology, Jeongeup, Republic of Korea.
  • Animal Production and Health Laboratory, Joint FAO/IAEA Centre of Nuclear Techniques in Food and Agriculture, Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Seibersdorf, Austria.
  • Department of Pediatrics, Ewha Womans University Mokdong Hospital, Seoul, Korea.
  • Department of Radiation Science, University of Science and Technology, Daejeon, Republic of Korea.

ORCID-Profile: Sun-Young Kim, Min-Kyu Kim, Kyung-Hyo Kim, Ki Bum Ahn, Ho Seong Seo

Förderung

  • Korea Atomic Energy Research Institute
  • Ministry of Science and ICT
  • Ministry of Food and Drug Safety
  • National Research Foundation of Korea
  • Korean government
  • International Atomic Energy Agency

Zitieren

APA

Kim, S. Y., Chen, F., Kim, W. S., Ji, H. J., Kim, M. K., Park, H. R., Lamien, C. E., Wijewardana, V., Kim, K. H., Ahn, K. B., & Seo, H. S. (2026). Epitope-Based Multimeric Subunit Vaccine (ATOMSSUISpenta) Confers Broad Protection Against Streptococcus suis Infection. The Journal of Infectious Diseases, 233(5), 899-911. https://doi.org/10.1093/infdis/jiag131

Vancouver

Kim SY, Chen F, Kim WS, Ji HJ, Kim MK, Park HR, et al. Epitope-Based Multimeric Subunit Vaccine (ATOMSSUISpenta) Confers Broad Protection Against Streptococcus suis Infection. The Journal of Infectious Diseases. 2026;233(5):899-911. doi:10.1093/infdis/jiag131

BibTeX
@article{Kim2026,
  author = {Kim, Sun-Young and Chen, Fengjia and Kim, Woo-Sik and Ji, Hyun Jung and Kim, Min-Kyu and Park, Hae Ran and Lamien, Charles Euloge and Wijewardana, Viskam and Kim, Kyung-Hyo and Ahn, Ki Bum and Seo, Ho Seong},
  title = {Epitope-Based Multimeric Subunit Vaccine (ATOMSSUISpenta) Confers Broad Protection Against Streptococcus suis Infection},
  journal = {The Journal of Infectious Diseases},
  year = {2026},
  volume = {233},
  number = {5},
  pages = {899--911},
  doi = {10.1093/infdis/jiag131}
}
Kostenlos starten →